oxalates and Precancerous-Conditions

oxalates has been researched along with Precancerous-Conditions* in 2 studies

Reviews

1 review(s) available for oxalates and Precancerous-Conditions

Article	Year
Renal cell carcinoma in acquired cystic kidney disease. Histopathology, 2010, Volume: 56, Issue:3 Topics: Carcinoma, Renal Cell; Humans; Kidney Diseases, Cystic; Kidney Neoplasms; Loop of Henle; Oxalates; Precancerous Conditions	2010

Other Studies

1 other study(ies) available for oxalates and Precancerous-Conditions

Article	Year
Modulation of doxorubicin sensitivity by a novel organic compound, oxalyl bis (N-phenyl) hydroxamic acid on acetyl aminofluorene-induced preneoplastic hepatocytes. Cancer letters, 2003, Dec-08, Volume: 202, Issue:1 Development of biochemical modulators and application of the same with anticancer drugs is a current approach of modern cancer chemotherapy. We report the effect of two novel hydroxamic acid derivatives, viz. oxaly bis (N-phenyl) hydroxamic acid (OBPHA) and succinyl bis (N-phenyl) hydroxamic acid (SBPHA) on doxorubicin sensitivity and on P-glycoprotein (P-gp) in acetyl amino fluorene (AAF) induced preneoplastic hepatocytes in vitro. OBPHA increases doxorubicin sensitivity in AAF induced preneoplastic hepatocytes compared to normal hepatocytes. SBPHA, with an additional -CH(2)-CH(2)- group than OBPHA does not modulate the sensitivity of doxorubicin. The mechanism of action of OBPHA and SBPHA and their in vivo toxicity on male Swiss mice has been studied. OBPHA in combination with doxorubicin (i.e. OBPHA+doxorubicin) has higher antitumour activity compared to doxorubicin alone group; in consequence, OBPHA may decrease the dose related side effect of doxorubicin. Topics: 2-Acetylaminofluorene; Animals; Antibiotics, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzeneacetamides; Calcium Channel Blockers; Carcinogens; Cell Division; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Drug Therapy, Combination; Glutathione; Hepatocytes; Humans; Hydroxamic Acids; Male; Mice; Oxalates; Precancerous Conditions; Rats; Rats, Sprague-Dawley; Spleen; Survival Rate; Tumor Cells, Cultured; Verapamil	2003

Article

Year

Modulation of doxorubicin sensitivity by a novel organic compound, oxalyl bis (N-phenyl) hydroxamic acid on acetyl aminofluorene-induced preneoplastic hepatocytes.

Cancer letters, 2003, Dec-08, Volume: 202, Issue:1

Development of biochemical modulators and application of the same with anticancer drugs is a current approach of modern cancer chemotherapy. We report the effect of two novel hydroxamic acid derivatives, viz. oxaly bis (N-phenyl) hydroxamic acid (OBPHA) and succinyl bis (N-phenyl) hydroxamic acid (SBPHA) on doxorubicin sensitivity and on P-glycoprotein (P-gp) in acetyl amino fluorene (AAF) induced preneoplastic hepatocytes in vitro. OBPHA increases doxorubicin sensitivity in AAF induced preneoplastic hepatocytes compared to normal hepatocytes. SBPHA, with an additional -CH(2)-CH(2)- group than OBPHA does not modulate the sensitivity of doxorubicin. The mechanism of action of OBPHA and SBPHA and their in vivo toxicity on male Swiss mice has been studied. OBPHA in combination with doxorubicin (i.e. OBPHA+doxorubicin) has higher antitumour activity compared to doxorubicin alone group; in consequence, OBPHA may decrease the dose related side effect of doxorubicin.

Topics: 2-Acetylaminofluorene; Animals; Antibiotics, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzeneacetamides; Calcium Channel Blockers; Carcinogens; Cell Division; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Drug Therapy, Combination; Glutathione; Hepatocytes; Humans; Hydroxamic Acids; Male; Mice; Oxalates; Precancerous Conditions; Rats; Rats, Sprague-Dawley; Spleen; Survival Rate; Tumor Cells, Cultured; Verapamil

2003